The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.85, a high estimate of $68.00, ...

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $28.10, denoting a -0.14% change from the preceding trading day.

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Since April 2020, the S&P 500 has delivered a total return of 92.9%. But one standout stock has nearly doubled the market - ...

Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Learn more ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Citi lowered the firm’s price target on Hims & Hers to $25 from $27 and keeps a Sell rating on the shares. The firm also added a “downside ...

Hims & Hers Health (HIMS) stock declined about 2% yesterday. The fall came after the U.S. Food and Drug Administration (FDA) ...

Still, plenty of men ask: Do women like beards? The short answer: It depends on the woman, the man, and the style.

Hims & Hers Health's HIMS short percent of float has risen 5.54% since its last report. The company recently reported that it ...

The FDA’s alert does not prevent Hims Hers Health from continuing to sell the treatment, but it raises questions about the future of these products in the market. The agency has stressed that ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...